Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2024)

Barinthus Biotherapeutics has reported Net Margin for 5 years, with the latest figure at 54.31% in Q3 2024.

• For the quarter ending Q3 2024, Net Margin changed N/A year-over-year to 54.31%; the trailing twelve-month figure through Dec 2025 stood at 443.97% (down 3524.0% YoY), and the FY2024 full-year result was 408.73%, up 874925.0% from the prior year.
• Net Margin for Q3 2024 stood at 54.31%, up from 7132.93% in the prior quarter.
• The five-year high for Net Margin was 1671800.0% in Q4 2021, with the low at 48162.86% in Q2 2021.
• Historically, Net Margin has averaged 104950.17% across 5 years, with a median of 659.43% in 2020.
• Annual changes were most pronounced in 2021 — Net Margin soared 167526441 bps — and 2022, when it slumped 167212775 bps.
• Barinthus Biotherapeutics' Net Margin stood at 3464.41% in 2020, then soared by 48356 bps to 1671800.0% in 2021, then tumbled by 100 bps to 327.75% in 2022, then slumped by 2076 bps to 7132.93% in 2023, then jumped by 99 bps to 54.31% in 2024.
• The last three Net Margin figures came in at 54.31% (Q3 2024), 7132.93% (Q2 2023), and 3893.8% (Q1 2023), per Business Quant data.